PFEPfizerRunning, no new patients
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Carcinoma, Non-Small-Cell Lung
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 296 (final count)
- Started
- Apr 27, 2017
- Main results expected
- Mar 20, 2020
- Fully finished
- Dec 31, 2028
- Results posted
- Apr 1, 2021
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) Assessment
Measured over: From time of Study Start up to 33 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03052608 · record last updated 2025-11-25 · checked 2026-11-09 15:36 UTC